RA disease duration was longer among patients who were positive for anti-PAD4 antibodies only (N = 26) and those with cross-reactive anti-PAD4/PAD3 antibodies (N = 20) than in patients who were negative for either of these antibodies (N = 146) (Table 1). The gene discussed is PADI4; the disease is rheumatoid arthritis.